TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevalence of Major Congenital Malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of days with migraine headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viral burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cytokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Femoral alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cup anteversion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cup inclination angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in depression features
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Purchasing Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in Adult Consumption Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes in Child Consumption Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage change in the total score of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bouts of recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl-Meyer Arm score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of distal radial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Manuscript acceptance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean temporal biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Composite Endpoint (CV Death or HF Readmission)
Endpoint domain: Mortality/survival
Primary endpoint: Change in left ventricular (LV) Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airtrapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Brachial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum IgG1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of functional embarrassment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of sequential therapy in treating community-acquired pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Non-progression Rate (NPR) at 27 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: new congestive heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving controlled haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported Minutes of Moderate-intensity Physical Activity per Week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-bronchodilator forced oscillation technique measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Objective response (complete response or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease control (stable disease or better)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OABq-SF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Toxicity as Assessed by NCI CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: Event-free Survival at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival at 24 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in Bone Mineral Density (Tb. BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma HIV-1 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in treating supraventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: individual physical endurance capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with obstructive sleep apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: incidence of primary non function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in CGI (Clinician Global Impression Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in PGI (Patient Global Impression Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative time from 999 call to discharge from care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Leukocyte telomere length (LTL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-transplant treatment-related mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Neurodevelopmental milestones
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Severe opportunistic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Positive change in MRI-inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximum plasma concentration of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under plasma concentration-time curve of simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under plasma concentration-time curve of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detected QRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Worst Lesional Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median Change in Average Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol awakening curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time in hypoglycemia (plasma glucose < 3.9 mmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fMRI differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of GTCS detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Over Time in Serum Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline Over Time in Serum iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Infarct size (% of left ventricle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of autoantibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stroke-specific measure of quality of life - Stroke Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: upper limb function assessed using the Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper limb motor control assessed using the Fugl-Meyer Assessment-upper extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of plasma triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of plasma triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with insulin independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CV drug ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Premenstrual Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in fMRI activation in amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in VAS score in response to Public Speaking stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects with AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically relevant changes from baseline in Draize Scale, physical examinations, vital signs, laboratory assessments, and electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of drug levels in the blood of treated patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: salt sensitivity of ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of successfully placed Uterine Manipulator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: False positive rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delay to implement antithrombotic and/or antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total number of minutes of activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of minutes of inactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of hypoparathyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy of HCV RNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood 25 Hydroxyvitamin D (25OHD) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of immediate PV isolation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC (0-inf) of RSG XR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response-rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Scintigraphic activity score for small bowel disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endothelial function in shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maraviroc plasma pharmacokinetic parameters (AUCτ, Cmax, Cτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amprenavir and ritonavir plasma pharmacokinetic parameters (AUCτ, Cmax, Cτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Flow at 75% of Expired Volume (FEF75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in total score of ADHD RS IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under curve 0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in anatomy and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change from baseline to Week 20 in the weekly itch score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective pathological responses (pT0 change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropsychological Assessment Battery- Screening score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of PEAP
Endpoint domain: Mortality/survival
Primary endpoint: Difference between peritoneal and central temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acceptability of an oral solution of glibenclamide
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline Modified Kupperman Index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate in production of SARS-CoV-2 specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Jamar's Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose absorption measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of grade II-IV acute GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Pediatric Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage reduction of daily average score of painful intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cartilage repair tissue assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective Response Rate (ORR, CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change of glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Observed maximum plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug concentration-plasma time curve from time zero to last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMC120 (dapivirine) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anti-diabetes Medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Answer at treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Atopic Dermatitis (AD) flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Angiogenesis capacity in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mayo Elbow Performance Score (MEPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quick Disability of Arm Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form - 36 (SF-36) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom resolution during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of eligible patients recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in mental well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in well-being (flourishing)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bacterial aetiology of middle ear fluid samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Impact of diagnostic imaging in assessing COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical management of COPD in relation to therapy adjustment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of sessions to complete variceal obliteration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of iron saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Confirmed-progression-free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in neutrophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Docetaxel AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety Disorder Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grief Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coping Mechanisms Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychiatric Morbidity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Symptoms Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Binge Eating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: overall quantity of physical activity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response Rate at Test of Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bowel dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of participants without stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the UPDRS Motor Score (Part III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reduction in Episodic Oxygen Desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the serum insulin icodec concentration-time curve after a single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma 25-hydroxy Vitamin D Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Degree of Platelet Inhibition (P2Y12 Reaction Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma Concentration of Clopidogrel and Prasugrel Active Metabolite and Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well child care outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of Laryngeal Mask Airway (LMA) insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cumulative duration of mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional Capacity-6-Minute Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factorial analysis of the Italian version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total serum IgG antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Memorial Symptom Assessment Scale (MSAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Growth (weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion grade at 12 month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of platelet counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of inflammatory markers in middle ear effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in systolic BP (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in diastolic BP (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes